Get the Daily Brief
Latest Biotech News
Regeneron’s cemdisiran advances toward FDA filing in myasthenia gravis
Regeneron reported positive Phase 3 results for cemdisiran, a small interfering RNA therapy licensed from Alnylam, targeting generalized myasthenia gravis, a rare neuromuscular autoimmune disease....
Wugen secures $115M for off-the-shelf CAR-T therapy trial
Wugen, a biotech focused on allogeneic CAR-T therapies, raised $115 million in a financing round led by Fidelity Management & Research and supported by multiple investors. The proceeds will fund...
Massachusetts biotech faces funding declines amid policy uncertainty
MassBio’s annual report revealed steep declines in public and private funding for Massachusetts’ biotech sector in the first half of 2025, with venture capital investments dropping more than 17%...
Scientists produce first full botulinum toxin complex structure
Researchers at Stockholm University employed cryo-electron microscopy to reveal the molecular architecture of the complete 14-subunit botulinum neurotoxin type B1 complex. This toxin, the most...
Pioneering roadmap of primate ovarian reserve development offers fertility insights
A collaborative team from UCLA, Harvard, UCSF, and the Oregon National Primate Research Center mapped cellular and molecular stages of ovarian reserve formation in rhesus macaques, which share...
AI-designed protein binders achieve unprecedented success rates
Researchers at École Polytechnique Fédérale de Lausanne released BindCraft, an automated computational pipeline enabling de novo design of functional protein binders with significantly enhanced...
Lilly’s Oral GLP-1 Pill Shows Dual Efficacy in Obesity and Diabetes
Eli Lilly has announced positive Phase 3 trial results for orforglipron, an oral GLP-1 receptor agonist targeting obesity and type 2 diabetes. In the 72-week Attain-2 trial, patients treated with...
AbbVie’s $1.2B Bet on Psychedelic Depression Therapy
AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead psychedelic candidate bretisilocin for up to $1.2 billion, signaling its expansion into emerging psychiatric medicine. Bretisilocin, a...
Regeneron’s RNAi Drug Meets Phase III Endpoints in Myasthenia Gravis
Regeneron's small interfering RNA (siRNA) therapeutic cemdisiran demonstrated robust efficacy in a Phase III trial for generalized myasthenia gravis, significantly reducing complement factor 5...
Breakthrough AI Model Boosts Functional Protein Design Success
Researchers at EPFL have developed BindCraft, a cutting-edge AI pipeline that achieves unprecedented success rates (10–100%) in functional protein binder design with strong affinity, bypassing...
Wugen Secures $115M to Advance Off-the-Shelf CAR-T Therapy for T-Cell Malignancies
Wugen has raised $115 million led by Fidelity Management & Research to fund pivotal trials for WU-CART-007, its allogeneic CAR-T therapy for relapsed or refractory T-cell acute lymphoblastic...
Lilly’s Verzenio Extends Survival in Early Breast Cancer Patients
Eli Lilly’s CDK4/6 inhibitor Verzenio significantly extended overall survival in the monarchE trial among patients with hormone receptor-positive, HER2-negative early breast cancer with high...
Massachusetts Biotech Faces Funding Declines Amid Federal Policy Challenges
MassBio’s annual report reveals a sharp downturn in Massachusetts biotech funding with venture capital investments dropping over 17% in H1 2025 to $2.75 billion, the lowest since 2017. Compounding...
Regulatory and Clinical Progress Highlights in Biopharma on August 26, 2025
Recent industry updates include multiple clinical trial initiations and data readouts from companies such as Akeso, Argenx, Eli Lilly, and Regeneron. Regulatory actions feature new drug...
Advancements in Organ Transplantation and Preservation Techniques
Pioneering studies in organ transplantation emphasize innovations in normothermic regional perfusion and the molecular underpinnings of xenotransplantation. Recent findings reveal that genetically...
New AI and Computational Tools Revolutionize Biomedical Research and Drug Discovery
The rise of AI-powered platforms is transforming biomedical research—from Ultrack’s state-of-the-art cell tracking in embryology to MARQO's computational cancer tissue analysis. Novel pipelines...
AbbVie Acquires Gilgamesh Psychedelic Drug in $1.2 Billion Deal
AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead clinical candidate, bretisilocin (GM-2505), a psychedelic compound in Phase II development for major depressive disorder (MDD). The...
Regeneron’s RNA Drug Cemdisiran Meets Phase III Goals for Myasthenia Gravis
Regeneron Pharmaceuticals announced positive Phase III results for cemdisiran, an siRNA therapeutic licensed from Alnylam Pharmaceuticals for generalized myasthenia gravis (MG). The monotherapy...
Lilly Advances Oral GLP-1 Pill with Phase III Obesity and Diabetes Trial Success
Eli Lilly reported positive Phase III data for orforglipron, an oral GLP-1 receptor agonist, in adults with obesity and type 2 diabetes. All doses met primary and key secondary endpoints,...
Pig-to-Human Lung Transplant Sustains Function for Nine Days
In a milestone for xenotransplantation, researchers performed the first pig-to-human lung transplant, where a genetically modified pig lung remained viable for nine days in a brain-dead...